Physician profile
Ann Voss
NPI 1457443772
$3,111.05
in general payments reported to CMS, 2019-2025
20 companies · $476 in 2025
The $476 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $378 · 2021: $565 · 2022: $414 · 2023: $256 · 2024: $750 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $918.41 | 2019-2024 | Precision 1 |
| Visioneering Technologies, INC. | $564.27 | 2019-2025 | |
| Coopervision INC. | $463.82 | 2020-2025 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $177.89 | 2023-2025 | Infuse, Vyzulta, Miebo |
| Sun Pharmaceutical Industries INC. | $168.54 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $160.55 | 2019-2024 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $96.47 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $79.04 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $76.04 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $66.78 | 2022-2023 | |
| Harrow Eye, LLC | $60.42 | 2024-2025 | Vevye |
| Shire North American Group INC | $53.19 | 2019 | |
| Abbvie INC. | $51.55 | 2022 | |
| Optos, INC. | $38.01 | 2021 | |
| Dompe US, INC. | $25.22 | 2025 | Oxervate |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $23.63 | 2022 | |
| Oyster Point Pharma, INC. | $23.08 | 2022 | |
| Thea Pharma INC. | $22.19 | 2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $21.60 | 2019 | |
| Allergan, INC. | $20.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Voss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.